FibroGen, Inc. (1FG.F)

Compare

0.3715

-0.0008

(-0.21%)

At close: 8:08:28 AM GMT+1

FibroGen sells China unit to AstraZeneca for $160m

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney disease.

Pharmaceutical Technology 11 days ago

AZN

FGEN
FibroGen to Sell China Unit to AstraZeneca for $160 Million

FibroGen (FGEN) said Thursday it has agreed to sell its China subsidiary to AstraZeneca (AZN) for ab

PREMIUM
MT Newswires 11 days ago

FGEN

AZN
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal

The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, AstraZeneca's biggest international market that accounted for 12% of 2024 sales, following heavy investments in the region. AstraZeneca in 2023 signed several licensing deals with Chinese companies and bought Suzhou-headquartered Gracell Biotechnologies for $1.2 billion. Earlier this month, the company reassured investors that the impact of several probes in China could be minor.

Reuters 11 days ago

FGEN

AZN
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure Company’s cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer

GlobeNewswire 11 days ago

FGEN
AstraZeneca deepens China presence with FibroGen deal

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there.

BioPharma Dive 11 days ago

FGEN

AZN
Several Insiders Invested In FibroGen Flagging Positive News

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. 27 days ago

FGEN
FibroGen Appoints David DeLucia as Chief Financial Officer

SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen’s global finance organization. He has most recently served as FibroGen’s Vice President, Head of Corporate Financial Planning and A

GlobeNewswire 2 months ago

FGEN
FibroGen Third Quarter 2024 Earnings: Beats Expectations

FibroGen ( NASDAQ:FGEN ) Third Quarter 2024 Results Key Financial Results Revenue: US$46.3m (up 15% from 3Q 2023). Net...

Simply Wall St. 3 months ago

FGEN
Q3 2024 FibroGen Inc Earnings Call

Q3 2024 FibroGen Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

FGEN

AZN
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions

FibroGen Inc (FGEN) reports a significant increase in Roxadustat sales in China and a substantial reduction in operating expenses, despite facing potential generic competition and a net loss.

GuruFocus.com 3 months ago

FGEN
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 55.26% and 36.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

FGEN
FibroGen: Q3 Earnings Snapshot

SAN FRANCISCO (AP) — FibroGen Inc. FGEN) on Tuesday reported a loss of $17.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss of 17 cents.

Associated Press Finance 3 months ago

FGEN
FibroGen Reports Third Quarter 2024 Financial Results

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over

GlobeNewswire 3 months ago

FGEN
FibroGen to Report Third Quarter 2024 Financial Results

SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: Click here To access the call, participan

GlobeNewswire 3 months ago

FGEN
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts

FibroGen Inc (FGEN) reports significant revenue increases and strategic pivots amid challenges in clinical trials and market competition.

GuruFocus.com 4 months ago

FGEN
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 10 at 3:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here. FibroGen’s managemen

GlobeNewswire 5 months ago

FGEN
FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

A week ago, FibroGen, Inc. ( NASDAQ:FGEN ) came out with a strong set of second-quarter numbers that could potentially...

Simply Wall St. 6 months ago

FGEN
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 38.46% and 53.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

FGEN
FibroGen: Q2 Earnings Snapshot

SAN FRANCISCO (AP) — FibroGen Inc. FGEN) on Tuesday reported a loss of $15.5 million in its second quarter. On a per-share basis, the San Francisco-based company said it had a loss of 16 cents.

Associated Press Finance 6 months ago

FGEN
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus R&D investment on FG-3246 and PET46, a first-in-class anti-CD46 antibody-drug conjugate and companion PET imaging agent for metastatic castration-resistant prostate cancer (mCRPC) Presented compelling preliminary data from dose escalation portion of Phase 1b/2 investigator-sponsored study of FG-3246,

GlobeNewswire 6 months ago

FGEN

Performance Overview

Return	1FG.F	S&P 500
YTD	-37.20%	-0.54%
1-Year	-76.03%	+13.87%
3-Year	-96.90%	+34.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

FibroGen, Inc. (1FG.F)

FibroGen sells China unit to AstraZeneca for $160m

FibroGen to Sell China Unit to AstraZeneca for $160 Million

AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

AstraZeneca deepens China presence with FibroGen deal

Several Insiders Invested In FibroGen Flagging Positive News

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 FibroGen Inc Earnings Call

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates

FibroGen: Q3 Earnings Snapshot

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen: Q2 Earnings Snapshot

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

Performance Overview